Key Financial Disclosures
Type of Issue:
Type: Rights Issue of Equity Shares
Amount to be Raised: ₹13,000 million (assuming full subscription)
Purpose of Proceeds:
- Pre-payment or repayment of outstanding borrowings: ₹8,105 million
- Funding research and development initiatives: ₹1,100 million
- Funding inorganic growth through unidentified acquisitions and other strategic initiatives and general corporate purposes: [●] million
Terms and Structure of the Issue:
Face Value: ₹2 per equity share
Issue Price: ₹[●] per rights equity share (including a premium of ₹[●] per share)
Entitlement Ratio: [●] Rights Equity Shares for every [●] fully paid-up equity shares held
Premium/Discount to Market Price: To be determined
Board/Committee Decisions:
Decisions made by the Board:
- constituted Fund Raising Committee comprising Venkaiah Chowdary Nannapaneni (Chairman), Rajeev Nannapaneni (Member) and Potluri Sivaramakrishna Prasad (Member)
- Approved rights issue structure and terms
- Authorized filing of draft letter of offer
Strategic Impact:
- Will reduce outstanding indebtedness of ₹9,543 million (consolidated as of August 31, 2026)
- Improve debt-to-equity ratio and financial parameters
- Enhance R&D capabilities in complex generics and specialty oncology products
Other Noteworthy Updates:
Issue Schedule:
- Last date for credit of Rights Entitlements: [●]
- Issue Opening Date: [●]
- Last date for On Market Renunciation: [●]
- Issue Closing Date: [●]
- Finalization of Basis of Allotment: [●]
- Date of Allotment: [●]
- Date of Credit of Rights Equity Shares: [●]
- Date of Listing: [●]
Promoter Participation: Promoters holding 49.42% as of June 30, 2026 intend to subscribe to their rights entitlement in full or part and may renounce portion
Monitoring Agency: Crisil Ratings Limited appointed to monitor utilization of gross proceeds
Outstanding Litigation: Company involved in 14 matters by company and 16 matters against company, including patent infringement cases, with amounts not quantifiable